Vaccine approaches to prevent and treat prion infection: Progress and challenges

BioDrugs

Volumn 22, Issue 1, 2008, Pages 45-52

  Müller Schiffmann, Andreas ^a   Korth, Carsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Prion infections; Research and development; Vaccines, general

Indexed keywords

CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; ICSM 18 MONOCLONAL ANTIBODY; ICSM 35 MONOCLONAL ANTIBODY; LAMININ RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6H4MU; PRION PROTEIN; PRION PROTEIN ANTIBODY; RECOMBINANT PRION PROTEIN; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY TITER; CELL ASSAY; CODON; DNA IMMUNIZATION; GENE; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMORAL IMMUNITY; IC 50; IMMUNE RESPONSE; NONHUMAN; PASSIVE IMMUNIZATION; PRION DISEASE; PRION GENE; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; VACCINATION; WILD TYPE;

EID: 38549173623     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822010-00005     Document Type: Review

References (78)

1. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95: 13363-83
2. Prusiner SB, Williams E, Laplanche J-L, et al. Scrapie, chronic wasting disease, and transmissible mink encephalopathy. In: Prusiner SB, editor. Prion biology and diseases. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2004: 545-94
3. Williams ES, Miller MW. Chronic wasting disease in deer and elk in North America. Rev Sci Tech 2002; 21 (2): 305-16
4. Kong Q, Surewicz KA, Petersen RB, et al. Inherited prion diseases. In: Prusiner SB, editor. Prion biology and diseases. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2004: 673-775
5. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66: 255-65
6. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977; 197: 943-60
7. Leopoldt JG. Der Trab ist auch eine Krankheit der Schafe, und ist ansteckend. In: Sorau H-PWdH, editor. Nützliche und auf Erfahrung gegründete Einleitung zu der Landwirtschaft. Berlin: Christian Friedrich Günthern, 1759
8. Collins S, Law MG, Fletcher A, et al. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999; 353 (9154): 693-7
9. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5
10. Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A 1999; 96: 15137-42
11. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363 (9407): 417-21
12. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-44
13. Pan K-M, Baldwin M, Nguyen J, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 1993; 90: 10962-6
14. Safar JG, Kellings K, Serban A, et al. Search for a prion-specific nucleic acid. J Virol 2005; 79: 10796-806
15. Harper JD, Lansbury Jr PT. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997; 66: 385-407
16. Brown P, Gibbs Jr CJ, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35: 513-29
17. Leliveld SR, Korth C. The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases. J Neurosci Res 2007; 85: 2285-97
18. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7
19. Bockman JM, Kingsbury DT. Immunological analysis of host and agent effects on Creutzfeldt-Jakob disease and scrapie prion proteins. J Virol 1988; 62: 3120-7
20. Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003; 302: 871-4
21. Mallucci GR, White MD, Farmer M, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007; 53: 325-35
22. Gabizon R, McKinley MP, Groth D, et al. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci U S A 1988; 85: 6617-21
23. Butler DA, Scott MRD, Bockman JM, et al. Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J Virol 1988; 62: 1558-64
24. Race RE, Fadness LH, Chesebro B. Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol 1987; 68: 1391-9
25. Bosque PJ, Prusiner SB. Cultured cell sublines highly susceptible to prion infection. J Virol 2000; 74: 4377-86
26. Caughey B, Race RE. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 1992; 59: 768-71
27. Supattapone S, Nguyen H-OB, Cohen FE, et al. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 1999; 96: 14529-34
28. Korth C, May BCH, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001; 98: 9836-41
29. Klingenstein R, Lober S, Kujala P, et al. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 2006; 98: 748-59
30. Kascsak RJ, Rubenstein R, Merz PA, et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 1987; 61: 3688-93
31. Rogers M, Serban D, Gyuris T, et al. Epitope mapping of the Syrian hamster prion protein utilizing chimeric and mutant genes in a vaccinia virus expression system. J Immunol 1991; 147: 3568-74
32. Büeler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73: 1339-47
33. Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 1993; 90: 10608-12
34. Sc)-specific epitope defined by a monoclonal antibody. Nature 1997; 389: 74-7
35. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 2001; 98: 9295-9
36. Beringue V, Vilette D, Mallinson G, et al. PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J Biol Chem 2004; 279: 39671-6
37. Perrier V, Solassol J, Crozet C, et al. Anti-PrP antibodies block PrP replication in prion-infected cell cultures by accelerating PrP degradation. J Neurochem 2004; 89: 454-63
38. Kim CL, Karino A, Ishiguro N, et al. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 2004; 85: 3473-82
39. Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739-43
40. Sc interactions. J Biol Chem 2007; 282: 7465-71
41. Riek R, Hornemann S, Wider G, et al. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett 1997; 413: 282-8
42. Demart S, Fournier J-G, Creminon C, et al. New insight into abnormal prion protein using monoclonal antibodies. Biochem Biophys Res Commun 1999; 265: 652-7
43. Feraudet C, Morel N, Simon S, et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 2005; 280: 11247-58
44. Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006; 63: 497-501
45. Paramithiotis E, Pinard M, Lawton T, et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 2003; 9: 893-9
46. Moroncini G, Kanu N, Solforosi L, et al. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc Natl Acad Sci U S A 2004; 101: 10404-9
47. Solforosi L, Criado JR, McGavern DB, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004; 303: 1514-6
48. Donofrio G, Heppner FL, Polymenidou M, et al. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005; 79: 8330-8
49. Telling GC, Scott M, Mastrianni J, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995; 83: 79-90
50. Leucht C, Simoneau S, Rey C, et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 2003; 4: 290-5
51. Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37kDa/67kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2088; 45: 144-51
52. Heppner FL, Musahl C, Arrighi I, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001; 294: 178-82
53. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422: 80-3
54. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54
55. Barry RA, McKinley MP, Bendheim PE, et al. Antibodies to the scrapie protein decorate prion rods. J Immunol 1985; 135: 603-13
56. Gilch S, Wopfner F, Renner-Muller I, et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 2003; 278: 18524-31
57. Rosset MB, Ballerini C, Gregoire S, et al. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 2004; 172: 5168-74
58. Arbel M, Lavie V, Solomon B. Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization. J Neuroimmunol 2003; 144: 38-45
59. Schwarz A, Kratke O, Burwinkel M, et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003; 350: 187-9
60. Nikles D, Bach P, Boller K, et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol 2005; 79: 4033-42
61. Handisurya A, Gilch S, Winter D, et al. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. FEBS J 2007; 274: 1747-58
62. Ishibashi D, Yamanaka H, Yamaguchi N, et al. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion. Vaccine 2007; 25: 985-92
63. Tal Y, Souan L, Cohen IR, et al. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J Neurosci Res 2003; 71: 286-90
64. Oxenius A, Martinic MM, Hengartner H, et al. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol 1999; 73: 4120-6
65. Vabulas RM, Pircher H, Lipford GB, et al. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 2000; 164: 2372-8
66. Sethi S, Lipford G, Wagner H, et al. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002 Jul 20; 360 (9328): 229-30
67. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10: 187-92
68. Polymenidou M, Heppner FL, Pellicioli EC, et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci U S A 2004; 101 Suppl. 2: 14670-6
69. Souan L, Tal Y, Felling Y, et al. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur J Immunol 2001; 31: 2338-46
70. Gregoire S, Logre C, Metharom P, et al. Identification of two immunogenic domains of the prion protein - PrP - which activate class II-restricted T cells and elicit antibody responses against the native molecule. J Leukoc Biol 2004; 76: 125-34
71. Gregoire S, Bergot AS, Feraudet C, et al. The murine B cell repertoire is severely selected against endogenous cellular prion protein. J Immunol 2005; 175: 6443-9
72. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003; 100: 2023-8
73. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005; 23: 3876-86
74. Wilesmith JW, Ryan JB, Atkinson MJ. Bovine spongiform encephalopathy: epidemiological studies on the origin. Vet Rec 1991; 128: 199-203
75. Miller MW, Wild MA, Williams ES. Epidemiology of chronic wasting disease in captive Rocky Mountain elk. J Wildl Dis 1998; 34: 532-8
76. Bade S, Baier M, Boetel T, et al. Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy. Vaccine 2006; 24: 1242-53
77. Goni F, Knudsen E, Schreiber F, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005; 133: 413-21
78. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-9